What's Happening?
A 300 billion won donation from the family of the late Samsung Electronics Chairman Lee Kun-hee to Seoul National University Children's Hospital five years ago has yielded significant results in combating childhood cancer and rare diseases. The initiative,
known as the 'Lee Kun-hee Childhood Cancer and Rare Disease Overcoming Project,' has led to the diagnosis of 22,646 patients and treatment of 14,757 as of September. Key achievements include the establishment of Korea's first standard treatment protocol for pediatric acute lymphoblastic leukemia, which classifies patients into five risk groups using genome analysis and next-generation sequencing. Additionally, the project has discovered and diagnosed over 20 new types of previously unknown rare diseases. A national rare disease diagnosis network has been created, enabling regional hospitals to send samples to a central analysis center for diagnostic results within four to six weeks. The research collaboration system has also expanded, with supported projects increasing from seven in 2021 to 190 this year, involving 185 institutions and 1,411 medical professionals.
Why It's Important?
This project addresses critical healthcare disparities in Korea, where diagnosing rare diseases takes an average of 9.2 years and approximately 50% of patients remain undiagnosed. The scarcity of pediatric hematologist-oncologists (only 69 nationwide) means many children outside Seoul must travel for treatment. By establishing a nationwide diagnostic network and standardizing treatment protocols, the initiative aims to provide equitable access to specialized care, regardless of a patient's location. The integration of advanced genomic analysis and precision medicine techniques is transforming the approach to pediatric oncology and rare diseases, offering more targeted and effective treatments. This philanthropic endeavor demonstrates how private funding can catalyze significant advancements in medical research and patient care, setting a precedent for future collaborations between private entities and healthcare institutions.
What's Next?
The project team plans to further develop programs for early diagnosis and disease prevention. These include ultra-high-speed genetic testing for infants in intensive care units, newborn genome screening, prenatal diagnosis, and preimplantation genetic testing. The goal is to integrate these research achievements into clinical practice and medical policy to expand diagnostic and treatment opportunities for children with cancer and rare diseases. The ongoing expansion of the national research collaboration system, with increasing participation from medical institutions and professionals, suggests a continued focus on innovation and broader implementation of advanced medical solutions. International collaborative research is also a key focus for the project's future direction.
Beyond the Headlines
The initiative reflects the late Chairman Lee Kun-hee's philosophy of 'respect for human life' and concern for children, translating into a tangible legacy of medical progress. This project highlights the profound impact that substantial private donations can have on public health infrastructure and research capabilities, particularly in specialized and underserved medical fields. It also underscores the importance of a multi-faceted approach to healthcare challenges, combining advanced scientific research, clinical application, and policy integration. The long-term implications include not only improved survival rates and quality of life for affected children but also the potential for Korea to become a leader in pediatric precision medicine, fostering international collaboration and knowledge sharing in the fight against childhood diseases.
